Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysis | Publicación